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1867ST-segment elevation myocardial infarction (STEMI), at
the expense of an increase in iatrogenic bleeding complica-
tions (1,2). Major bleeding complications in patients un-
dergoing percutaneous coronary intervention (PCI) and in
patients with acute coronary syndromes are associated with
short-term mortality and morbidity, prolonged length of
stay, and greater resource consumption (3–5). Conse-
quently, inclusion of bleeding as a safety endpoint in ran-
domized controlled trials has become pivotal for the
assessment of new antithrombotic agents and interven-
tional techniques. In previous studies, a broad variety of
bleeding classiﬁcations have been used to report hemor-
rhagic complications. This variety has hampered direct
comparison of the incidence of bleeding complications
across different trials or even within studies, because re-
ported bleeding events may vary widely according to the
bleeding deﬁnition applied (6).
BARC (Bleeding Academic Research Consortium) has
recently developed a standardized hierarchical bleeding clas-
siﬁcation system (7). The prognostic value of BARC-deﬁned
bleeding complications was recently established in patients
with non–ST-segment elevation acute coronary syndrome
and in patients undergoing elective PCI but has not been
investigated in high-risk patients, such as in those with
STEMI (8). Furthermore, it is of particular interest to
investigate the prognostic impact of the individual data ele-
ments that comprise the BARC and other bleeding classiﬁ-
cations because this might contribute to further optimizing
bleeding deﬁnitions (9,10). Therefore, the aim of the present
study was: 1) to investigate the relationship of BARC
bleeding with 30-day and 1-year mortality; 2) to investigate
how the BARC bleeding deﬁnition compares with existing
bleeding deﬁnitions with regard to mortality prediction; and
3) to investigate the incidence and prognostic value of the
separate bleeding data elements that comprise the bleeding
deﬁnitions.
Methods
Source population and procedures. The data analyzed in
this study were obtained from STEMI patients accepted for
PPCI at the Academic Medical Center, University of
Amsterdam, between January 1, 2003, and July 31, 2008.
The study complied with the principles of the Declaration of
Helsinki, and the local ethics committee approved the study
protocol. In general, patients qualiﬁed for PPCI if they had
typical ischemic chest pain and at least a 1-mm ST-segment
elevation in 2 or more contiguous leads, a new left bundle
branch block, or a true posterior myocardial infarction. Pa-
tients received a standard 300- to 600-mg loading dose of
clopidogrel. If a coronary stent was implanted, clopidogrel
was prescribed for at least 1 month to patients with a bare
metal stent and for 6 to 12 months to patients with a drug-
eluting stent. Patients were routinely pretreated with
300 mg of aspirin and 5,000 IU of unfractionated heparin.
An additional heparin bolus was administered at thecatheterization laboratory if
necessary to achieve a targeted
activated clotting time of 300 s
followed by an infusion of 12 U/
kg/h with titration to achieve a
target activated partial thrombo-
plastin time (aPTT) of 1.5 to 2.0
times the control. Glycoprotein
IIb/IIIa inhibitors were used at the
discretion of the operator.
Procedural and angiographic
data were prospectively collected
and entered into a dedicated
database by interventional cardi-
ologists and specialized nurses.
Chart review for consecutive
STEMI patients with available
aPTT measurements was per-
formed in the context of a study
designed to investigate the rela-
tionship between aPTT and
clinical outcome in STEMI pa-
tients treated with PPCI. A de-
tailed description of the study
protocol has been published pre-
viously (11). Source documenta-
tion (laboratory results, discharge
letters, case history, and nurse
reports) was collected for every
hospital admission for each patient in both the PCI center
and in referring hospitals and was assessed for the occurrence
of clinical events, including hemorrhage. Follow-up infor-
mation regarding vital status was obtained from computer-
ized, long-term mortality records from the Dutch National
Death Index between January 1, 2012, and April 30, 2012.
STUDY DESIGN, BLEEDING DEFINITIONS, AND ADJUDICATION.
The study cohort consisted of all STEMI patients included
in our study database who were alive at the end of the
procedure. The primary outcome of this study was 1-year
all-cause mortality. All hospitalizations were reviewed for
the presence of bleeding by 1 author (W.J.K.) who had full
access to the patient’s clinical and laboratory records.
Complicated cases were discussed and adjudicated with 2
other authors (J.G.P.T. and J.P.S.H.). For each bleeding
event, the following items were recorded in the study
database: the date and source of the bleeding, the hemo-
globin decrease associated with the bleeding event (adjusted
for the amount of transfusions), the amount of blood
transfusions attributable to the bleeding event, the discon-
tinuation of antithrombotic therapy associated with bleeding
(as well as the use of aspirin, thienopyridine, vitamin K
antagonists, heparin, and glycoprotein IIb/IIIa inhibitors
before and after the bleeding was recorded), use of diag-
nostic procedures (including imaging techniques), surgery to
control bleeding, the use of vasoactive agents for bleeding,
Table 1
Baseline, Procedural, and Angiographic
Characteristics of the Study Patients
N ¼ 2,002
% Missing
Data
Male 1,406/2,002 (70.2) 0.0
Age, yrs 62.0  13.0 0.0
Body mass index, kg/m2 26.1 (24.1–28.9) 10.0
History of
IDDM 76/2,002 (3.8) 0.0
NIDDM 201/2,002 (10.0) 0.0
Hypertension 758/2,002 (37.9) 0.0
Hypercholesterolemia 462/2,002 (23.1) 0.0
Current smoking 872/2,002 (43.6) 0.0
Previous stroke or TIA 125/2,002 (6.2) 0.0
Peripheral vascular disease 131/2,002 (6.5) 0.0
Pre-existing malignant disease 155/2,002 (7.7) 0.0
Recent surgery (<10 days) 22/2,002 (1.1) 0.0
Bleeding 81/2,002 (4.0) 0.0
Previous MI 249/2,002 (12.4) 0.0
Previous PCI 187/2,002 (9.3) 0.0
Previous CABG 45/2,002 (2.2) 0.0
Family history of CAD 746/2,002 (37.3) 0.0
Laboratory values
White blood cell count
11  109/l
1,039/1,977 (52.6) 1.2
Anemia* 319/2,000 (16.0) 0.1
Creatinine clearance
<60 ml/min/1.73 m2y
322/1,817 (17.7) 9.2
In-hospital Hb decrease, g/dlz 1.4 (0.6–2.6) 0.1
In-hospital Hb decrease, g/dlz 0.1
<3 1549/1,938 (79.9)
3–5 265/1,938 (13.7)
5 124/1,938 (6.4)
Thrombocyte count, 109/l 1.0
<150 75/1,982 (3.8)
150–400 1,836/1,982 (92.6)
>400 71/1,982 (3.6)
Values are n/N (%), mean  SD, or median (interquartile range). *Anemia was deﬁned as baseline
hemoglobin (Hb) <13 g/dl for male subjects and <12 g/dl for female subjects. yCreatinine
clearance was estimated by using the Cockcroft-Gault equation. zDeﬁned as the baseline Hb
measurement subtracted by a nadir measurement (within 10 days of the baseline measurement)
in patients not undergoing coronary artery bypass graft (CABG).
CAD ¼ coronary artery disease; IDDM ¼ insulin-dependent diabetes mellitus; IQR ¼ interquartile
range; MI ¼ myocardial infarction; NIDDM ¼ non–insulin-dependent diabetes mellitus; PCI ¼
percutaneous coronary intervention; TIA ¼ transient ischemic attack.
Table 2
Procedural and Angiographic Characteristics of the
Study Patients
N ¼ 2,002
% Missing
Data
Total ischemic time, min 180 (130–264) 9.6
Cardiogenic shock 152/1,985 (7.7) 0.8
Intra-aortic balloon pump* 247/1,999 (12.4) 0.1
Loading dose clopidogrel 2.9
300 mg 1,240/1,944 (63.8)
600 mg 619/1,944 (31.8)
Other 11/1,944 (0.6)
Glycoprotein IIb/IIIa Inhibitor 564/2,002 (28.2) 0.0
PCI access site 0.1
Femoral artery 1,910/2,000 (95.5)
Radial artery 74/2,000 (3.7)
Other or combinations 16/2,000 (0.8)
Infarct related artery 3.2
RCA or LCX 1,090/1,937 (56.3)
LAD or LM 847/1,937 (43.7)
Pre-procedural TIMI ﬂow in IRA 10.0
0/1 1,313/1,801 (72.9)
2/3 488/1,801 (27.1)
Post-procedural TIMI ﬂow in IRA 5.5
0/1 61/1,891 (3.2)
2/3 1,830/1,891 (96.8)
Mulitvessel disease 715/1,925 (37.1) 3.8
Chronic total occlusion 270/1,925 (14.0) 3.8
Intracoronary thrombus 1,122/1,920 (58.4) 4.1
Ostial lesion 239/1,920 (12.4) 4.1
Calciﬁcation 391/1,920 (20.4) 4.1
Pre-existing dissection 350/1,920 (18.2) 4.1
Amount of lesions treated 0.0
1 1,880/2,002 (93.9)
2 39/2,002 (1.9)
3 3/2,002 (0.1)
Stent 0.0
Bare-metaly 1,655/1,700 (97.4)
Drug-eluting 45/1,700 (2.6)
Stent length, mm 18 (15–23) 0.2
Procedural characteristics in
patients undergoing CABG
during index hospitalization
(n ¼ 62)
Chest tube output within a 24-h
period, ml
795 (543–1,339) 12.9
Amount of packed red blood
cells within a 48-h period
4 (2–7) 0.0
Values are median (interquartile range) or n/N (%). *Includes 15 patients who received hemo-
dynamic support with the Impella percutaneous left ventricular assist device (Abiomed Europe
GmbH, Aachen, Germany). yIncludes 10 patients who were treated with an endothelial progenitor
cell capturing stent.
IRA ¼ infarct-related artery; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery;
LM ¼ left main coronary artery; RCA ¼ right coronary artery; TIMI ¼ Thrombolysis In Myocardial
Infarction; other abbreviations as in Table 1.
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tion, for all patients who underwent coronary artery bypass
graft (CABG), we recorded the need for reoperation because
of bleeding after closure of the sternum, the amount of blood
transfusions within a 48-h window post-CABG, and the
chest tube output in the ﬁrst 24 h after CABG.
Bleeding events occurring during the initial hospitaliza-
tion were assessed and classiﬁed according to TIMI
(Thrombolysis In Myocardial Infarction), GUSTO (Global
Utilization of Streptokinase and Tissue Plasminogen Acti-
vator for Occluded Coronary Arteries), ISTH (International
Society on Thrombosis and Haemostasis), and BARC
criteria (7,12–14). A detailed description of these bleeding
classiﬁcations is given in Online Table 1. If a patientexperienced multiple in-hospital bleeding events, the most
severe was classiﬁed rather than the ﬁrst event. The occur-
rence of BARC type 1 bleeding was not considered in the
present paper.
STATISTICAL ANALYSIS. For each bleeding classiﬁcation,
1-year mortality rates for the various bleeding categories
were estimated using Kaplan-Meier analyses. A landmark
Table 3
1-Year All-Cause Mortality According to
In-Hospital BARC Bleeding Type
No. of Patients 30-Day Mortality* 1-Year Mortality*
BARC type 0 or 1 1,601 (80.2) 101 (6.3) 146 (9.1)
BARC type 2 88 (4.4) 3 (3.4) 9 (10.2)
BARC type 3 280 (14.2) 51 (18.2) 67 (23.9)
Type 3a 170 (8.5) 26 (15.3) 36 (21.2)
Type 3b 109 (5.4) 24 (22.0) 30 (27.5)
Type 3c 1 (0.05) 1 (100.0) 1 (100.0)
BARC type 4 27 (1.4) 5 (18.5) 7 (25.9)
BARC type 5 6 (0.3) d d
Type 5a 5 (0.2) d d
Type 5b 1 (0.05) d d
Values are n (%). *Kaplan-Meier estimates.
BARC ¼ Bleeding Academic Research Consortium.
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1869was set at 30 days. BARC type 5 bleeding (fatal
bleeding) was not assessed as a separate bleeding category
because it is not possible to associate fatality itself with
mortality. To ensure a fair comparison with the other
bleeding classiﬁcations, patients with fatal bleedings were
excluded from the analyses. We calculated hazard ratios
for 1-year mortality for the different bleeding categories
of the TIMI, ISTH, GUSTO, and BARC bleeding
classiﬁcations by using univariable and multivariable Cox
regression analyses adjusting for baseline predictors of
mortality. To identify baseline variables with a signiﬁcant
unadjusted association with 1-year mortality, univariable
Cox regression analyses were ﬁrst performed for the
variables listed in Tables 1 and 2 (with the exception ofTable 4 1-Year All-Cause Mortality According to In-hospital Bleeding
n (%)
Mortality
% (n/N)* HR
ISTH
Minor or no bleeding 1,616 (80.7) 9.4 (151/1,616) 1.00
Major bleeding 380 (19.0) 20.5 (78/380) 2.30
GUSTO
Mild or no bleeding 1,814 (90.6) 9.9 (179/1,814) 1.00
Moderate bleeding 127 (6.3) 27.6 (35/127) 2.99
Severe bleeding 55 (2.7) 27.3 (15/55) 3.09
TIMI
Minimal or
no bleeding
1,710 (85.4) 9.4 (160/1,710) 1.00
Minor bleeding 159 (7.9) 20.1 (32/159) 2.28
Major bleeding 100 (5.0) 30.0 (30/100) 3.60
CABG related 27 (1.3) 25.9 (7/27) 3.09
BARC
Type 0 or 1 1,601 (80.0) 9.1 (146/1,601) 1.00
Type 2 88 (4.4) 10.2 (9/88) 1.11
Type 3a 170 (8.5) 21.2 (36/170) 2.45
Type 3b þ 3cz 110 (5.5) 28.2 (31/110) 3.43
Type 4 27 (1.3) 25.9 (7/27) 3.17
6 patients with fatal bleeding (BARC type 5) were excluded from the analysis. *Kaplan-Meier estimates.
zType 3b and 3c were combined because there was only 1 patient with BARC type 3c, and a separate
CI ¼ conﬁdence interval; GUSTO ¼ Global Utilization of Streptokinase and Tissue Plasminogen Activator
abbreviations as in Tables 1 and 3.in-hospital hemoglobin decrease and procedural data spe-
ciﬁc to CABG). To identify independent baseline pre-
dictors of 1-year mortality, we next performed a stepwise
backward selection Cox regression analysis including vari-
ables with a signiﬁcant association according to univariable
analysis (p < 0.10). The entry criterion was set at p <
0.05, and the exit criterion was set at p ¼ 0.10.
The increased discriminative value of the models after
addition of in-hospital bleeding (according to the different
bleeding deﬁnitions) to the baseline predictors of 1-year
mortality was estimated by using 3 measures: change in
Harrell’s c-index, net reclassiﬁcation improvement (NRI),
and integrated discrimination improvement (IDI) (15,16).
Bootstrapping (400 runs) was used to compare these mea-
sures among the different multivariable models. To inves-
tigate the prognostic value of the individual data elements of
the different bleeding classiﬁcations for 1-year mortality, we
developed additional Cox models. Details regarding these
models are described in the Online Appendix.
Data were complete for mortality and for 19 of 40
variables. Missing patient-level covariates were assumed
to be missing at random and were imputed with the use
of multiple imputations. The imputation procedure and
subsequent Cox proportional hazards regression estima-
tion, estimation of Harrell’s c-index, NRI, and IDI were
performed according to Rubin’s protocol (17,18). Analyses
were performed with SPSS version 19.0 (IBM SPSS
Statistics, IBM Corporation, Armonk, New York) and
R (R Foundation for Statistical Computing, Vienna,
Austria).Status for the Different Bleeding Deﬁnitions
Unadjusted Adjustedy
95% CI p Value HR 95% CI p Value
d d 1.00 d d
1.75–3.03 <0.001 1.17 0.88–1.57 0.28
d d 1.00 d d
2.08–4.29 <0.001 0.81 0.55–1.21 0.31
1.82–5.23 <0.001 1.56 0.91–2.68 0.11
d d 1.00 d d
1.56–3.33 <0.001 0.95 0.63–1.42 0.79
2.43–5.31 <0.001 2.00 1.32–3.01 0.001
1.45–6.59 0.003 1.34 0.62–2.90 0.45
d d 1.00 d d
0.57–2.17 0.77 0.96 0.49–1.90 0.91
1.70–3.52 <0.001 0.97 0.66–1.44 0.89
2.33–5.06 <0.001 1.84 1.23–2.77 0.003
1.49–6.77 0.003 1.34 0.62–2.89 0.46
yCalculated by using Cox proportional hazards models adjusting for the variables in Online Table 2.
hazard ratio (HR) was therefore not computable.
for Occluded Coronary Arteries; ISTH ¼ International Society on Thrombosis and Haemostasis; other
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Of the 2,009 STEMI patients recorded in our database, 7
patients died during the index PPCI. Baseline, procedural,
and angiographic characteristics of the remaining 2,002
patients included in the present analysis are given in
Tables 1 and 2. A total of 596 (29.8%) were women, and 277
(13.8%) had diabetes. Their mean age was 62 years, median
total ischemic time was 3 h, and cardiogenic shock was
present in 7.7% of patients. Sixty-two patients underwent
CABG during the index admission. Of the 1,938 patients
who did not undergo CABG and in whom hemoglobin
measurements were available, 389 (20.1%) had a decrease
in hemoglobin of at least 3 g/dl; 143 (36.8%) of these patients
had no observed blood loss. The incidence of BARC
bleeding types is shown in Table 3. Incidence of in-hospital
bleeding complications according to other bleeding deﬁni-
tions is shown in Table 4. Of the 62 patients who underwent
CABG during the index admission, 27 (43.5%) developed
BARC type 4 bleeding and 1 (1.6%) developed BARC type
5 bleeding. In patients with BARC type 4 bleeding, the
median amount of days from presentation until CABG was
0 (interquartile range: 0 to 6), whereas in patients withoutFigure 1
Landmark Cumulative Mortality Curves According to In-hos
Fatal Bleeding Events (n ¼ 1,996)
Shown are Kaplan-Meier curves for 1-year mortality with a landmark set at 30 days acco
Consortium), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activat
and ISTH (International Society on Thrombosis and Haemostasis) bleeding classiﬁcationsCABG-related bleeding, the median amount of days until
CABG was 6 (interquartile range: 1.5 to 13).
Prognostic value of bleeding complications according to
the different bleeding deﬁnitions. One-year survival status
was complete in 1,997 patients (99.8%). Multivariable pre-
dictors of 1-year mortality determined by using a stepwise
backward selection Cox proportional hazards model are
shown in Online Table 2. Figure 1 presents Kaplan-Meier
curves for 1-year mortality according to the different
bleeding classiﬁcations (with a landmark set at 30 days).
Table 3 presents the 30-day and 1-year mortality rates for
the separate BARC bleeding types. In patients undergoing
CABG during the index admission, 1-year mortality was
25.9% among those who developed BARC type 4 bleeding
and 5.9% among those who did not. Table 4 shows 1-year
mortality rates and unadjusted and adjusted hazard ratios
for 1-year mortality according to the different bleeding
classiﬁcations. Online Table 3 presents the 30-day mortality
rates and unadjusted and adjusted hazard ratios for 30 days’
mortality according to the different bleeding classiﬁcations.
Bleeding complications were associated with higher cumu-
lative mortality, irrespective of the applied bleeding deﬁni-
tion. However, after adjustment for baseline predictors ofpital Bleeding Status in Patients Without
rding to in-hospital bleeding status for the BARC (Bleeding Academic Research
or for Occluded Coronary Arteries), TIMI (Thrombolysis In Myocardial Infarction),
.
Figure 2
Premature Cessation of Antithrombotic Therapy in
Response to Bleeding Complications in Patients
Without Fatal Bleeding Events (n ¼ 1,996)
Dark blue bars indicate the proportion of patients in whom any antithrombotic
agent (e.g., aspirin, thienopyridine, glycoprotein IIB/IIIA inhibitor, vitamin K
antagonist, antithrombin agent) was temporarily discontinued in response to
bleeding. Light blue bars indicate the proportion of patients in whom aspirin or
thienopyridine treatment was prematurely discontinued indeﬁnitely in response to
bleeding. The rates of discontinuation increase with increasing BARC type.
Abbreviation as in Figure 1.
Figure 3
ROC Curves for the Different Multivariable Models in
Patients Without Fatal Bleeding Events (n ¼ 1,996)
Shown are adjusted receiver-operating characteristic (ROC) curves for the multi-
variable model with baseline predictors of mortality and the multivariable models
with baseline predictors of mortality and bleeding according to the TIMI, the ISTH,
GUSTO, and BARC bleeding classiﬁcations. Abbreviations as in Figure 1.
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1871mortality, only TIMI major bleeding and BARC type 3b or
3c bleeding continued to be associated with a higher risk of
1-year mortality. Figure 2 displays the rates of temporary
and indeﬁnite cessation of antithrombotic therapy in
response to bleeding according to the different BARC types.
Predictive value of bleeding complications according to
different bleeding deﬁnitions. The predictive value of
the multivariable model including baseline predictors was
excellent (Harrell’s c-index: 0.836). Adjusted receiver-
operating characteristic curves for the multivariable models,
including the baseline predictors of mortality and bleeding
complications according to the different bleeding deﬁni-
tions, are shown in Figure 3. There was no statistically
signiﬁcant improvement in Harrell’s c-index after addition
of any of the bleeding scales to the multivariable model
(Table 5). Nevertheless, classiﬁcation of patients who died or
were alive at 1-year follow-up signiﬁcantly improved after
addition of either TIMI (NRI: 0.222), ISTH (NRI: 0.339),
GUSTO (NRI: 0.305), or BARC (NRI: 0.181) to the
multivariable model with baseline predictors of mortality.Table 5 Discrimination of Cox Regression Models for 1-Year Mortalit
Harrell’s c-Index 95% CI p Value*
Multivariable 0.836 0.811–0.860 d
Multivariable þ TIMI 0.839 0.815–0.862 0.27
Multivariable þ ISTH 0.837 0.813–0.861 0.085
Multivariable þ GUSTO 0.836 0.812–0.860 0.91
Multivariable þ BARC 0.838 0.815–0.862 0.25
6 patients with fatal bleeding (BARC type 5) were excluded from the analysis. *p value for compariso
in Online Table 2).
c-index ¼ concordance index; IDI ¼ integrated discrimination improvement; NRI ¼ net reclassiﬁcation inHowever, the IDIs of the multivariable models including
TIMI, ISTH, and BARC bleeding complications were below
zero, indicating that the improvement in predicted proba-
bility of those correctly reclassiﬁed was smaller than the
worsening in predicted probability of those incorrectly
reclassiﬁed.Online Table 4 presentsHarrell’s c-indices, NRIs,
and IDIs of the multivariable models for 30-day mortality.
Prognostic value of the individual data elements of
bleeding deﬁnitions. Table 6 displays the incidence,
mortality rates, and unadjusted and adjusted hazard ratios
for 1-year mortality of the individual data elements of the
BARC, TIMI, GUSTO, and ISTH bleeding classiﬁcations.
Bleeding complications with a large hemoglobin decrease
(5 g/dl) and bleeding complications resulting in the need
for vasoactive agents were associated with a high risk of
subsequent mortality, although the latter did not reach
conventional statistical signiﬁcance (p ¼ 0.083). Intracranial
and hemopericardial bleeding complications were associatedy in STEMI Patients
NRI p Value* IDI (Absolute) IDI (Relative) p Value*
d d d d d
0.222 0.0016 –0.00272 –2.2 0.039
0.339 <0.001 –0.00106 –5.9 0.023
0.305 <0.001 –0.000186 –0.4 0.80
0.181 0.0098 –0.00332 –7.2 0.0050
n with the multivariable model including the independent baseline predictors of mortality (shown
dex; STEMI ¼ ST-segment elevation myocardial infarction; other abbreviations as in Tables 3 and 4.
Table 6 One-Year All-Cause Mortality According to BARC Bleeding Data Elements
Criterion n (%)
Mortality
n (%)*
Unadjusted Adjustedy
HR 95% CI p Value HR 95% CI p Value
BARC
Patients not undergoing CABG during
index admission (n ¼ 1,935)z
BARC type 2 1,659 (82.9) 154 (9.3) 1.00 . . 1.00 .
BARC type 3a 167 (8.3) 36 (21.6) 2.45 1.71–3.53 <0.001 0.95 0.64–1.41 0.79
Hb decrease 3–5 g/dl 149 (7.4) 31 (20.8) 2.37 1.61–3.49 <0.001 0.93 0.61–1.41 0.72
Transfusion 87 (4.3) 24 (27.6) 3.20 2.08–4.92 <0.001 0.73 0.45–1.18 0.21
BARC type 3b 108 (5.4) 29 (26.9) 3.18 2.14–4.73 <0.001 1.78 1.17–2.70 0.007
Hb decrease 5 g/dl 98 (4.9) 28 (28.6) 3.41 2.28–5.11 <0.001 1.94 1.26–2.98 0.003
Cardiac tamponade 6 (0.3) 2 (33.3) 4.29 1.06–17.3 0.041 2.38 0.56–10.1 0.24
Surgery for control 15 (0.7) 4 (26.7) 3.11 1.15–8.40 0.025 1.20 0.43–3.37 0.73
Vasoactive agents 17 (0.8) 7 (41.2) 5.67 2.66–12.1 <0.001 2.01 0.91–4.44 0.083
BARC type 3c 1 (0.0) 1 (100)
Intracranial hemorrhage 1 (0.0) 1 (100) .x . . .x . .
Intraocular bleeding 0 (0.0) 0 (0.0) .x . . .x . .
Patients undergoing CABG during
index admission (n ¼ 61)jj
No BARC type 4 bleeding 34 (1.7) 2 (5.9) 1.00 . . 1.00 . .
BARC type 4 27 (1.3) 7 (25.9) 5.02 1.04–24.2 0.044 2.17{ 0.23–20.8 0.50
Intracranial hemorrhage post-CABG 0 (0.0) 0 (0.0) .x – . .x . .
5 RBCs in 48-h period 27 (1.3) 7 (25.9) 5.02 1.04–24.2 0.044 2.17{ 0.23–20.8 0.50
Chest tube output 2 l in 24 h 7 (0.3) 1 (14.3) 0.99 0.12–7.90 0.99 1.87{ 0.16–21.6 0.62
Reoperation for bleeding 4 (0.2) 0 (0.0) .x . . .x . .
TIMI
Patients not undergoing CABG during
index admission (n ¼ 1,935)z
No TIMI major or minor bleeding 1,679 (83.9) 9.5 (159) 1.00 . . 1.00 . .
TIMI minor
Hb decrease 3–5 g/dl 157 (7.8) 20.1 (32.0) 2.28 1.56–3.33 <0.001 0.92 0.61–1.39 0.70
TIMI major
Intracranial hemorrhage 1 (0.0) 100 (1.0) .x . . .x . .
Hb decrease 5 g/dl 98 (4.9) 28.6 (28) 3.35 2.24–5.01 < 0.001 1.94 1.27–2.98 0.002
Patients undergoing CABG during
index admission (n ¼ 61)k
No TIMI CABG-related bleeding 34 (1.7) 2 (5.9) 1.00 . . 1.00 . .
TIMI CABG-related 27 (1.3) 7 (25.9) 5.02 1.04–24.2 0.044 2.17{ 0.23–20.8 0.50
5 PCIs in 48 h post-CABG 27 (1.3) 7 (25.9) 5.02 1.04–24.2 0.044 2.17{ 0.23–20.8 0.50
Chest tube output 2 l in 24 h 7 (0.3) 1 (14.3) 0.99 0.12–7.90 0.99 1.87{ 0.16–21.6 0.62
Reoperation 5 (0.2) 0 (0.0) .x . . .x . .
Continued on the next page
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1872with a high unadjusted mortality rate. For intracranial
hemorrhage, a hazard ratio for 1-year mortality was not
computable because there was only 1 patient with intracra-
nial bleeding.
Discussion
The main ﬁndings of the present analysis can be summa-
rized as follows. First, the incidence of BARC types 2, 3, 4,
and 5 bleeding was 4.4%, 14.2%, 1.4%, and 0.3%, respec-
tively. Second, BARC type 3b or 3c bleeding and TIMI
major bleeding were associated with a 2-fold higher risk of
1-year mortality. Addition of BARC, TIMI, GUSTO, or
ISTH bleeding classiﬁcations to a multivariable model withbaseline predictors of mortality improved the reclassiﬁcation
(NRI) but did not improve Harrell’s c-index or the IDI of
the multivariable models. Thus, the additive predictive value
of bleeding beyond conventional cardiovascular risk factors is
limited. Finally, data elements of bleeding deﬁnitions asso-
ciated with high mortality were intracranial and hemoper-
icardial bleeding, bleeding requiring the use of vasoactive
agents, and bleeding complications associated with a large
decrease in hemoglobin (5 g/dl).
Incidence of BARC-deﬁned bleeding complications in
STEMI. The incidence of the different BARC bleeding
types reported in the present study was higher than those re-
ported in a recently published pooled analysis of patients with
stable and unstable coronary artery disease undergoing PCI
Table 6 Continued
Criterion n (%)
Mortality
n (%)*
Unadjusted Adjustedy
HR 95% CI p Value HR 95% CI p Value
GUSTO
No GUSTO severe or moderate bleeding 1,814 (90.6) 9.9 (179) 1.00 . . 1.00 . .
GUSTO moderate
Bleeding requiring blood transfusion 127 (6.3) 27.6 (35) 2.99 2.08–4.29 <0.001 0.81 0.55–1.21 0.31
GUSTO severe
Intracranial hemorrhage 1 (0.0) 100 (1) .x . . –x . .
Bleeding with hemodynamic compromise 54 (2.7) 25.9 (14) 2.89 1.68–4.98 <0.001 1.39 0.80–2.44 0.24
ISTH
No ISTH major bleeding 1,616 (80.7) 9.4 (151) 1.00 . . 1.00 . .
ISTH major bleeding 380 (19.0)
Hb drop 2 g/dl or 2 RBC transfusion 379 (18.9) 20.6 (78) 2.32 1.76–3.05 <0.001 1.17 0.88–1.57 0.28
Hb drop 2 g/dl 368 (18.4) 20.4 (75) 2.29 1.74–3.02 <0.001 1.21 0.90–1.62 0.20
2 RBC transfusion 128 (6.4) 25.8 (33) 2.94 2.02–4.29 <0.001 0.81 0.54–1.23 0.33
Critical organ 18 (0.9) 16.7 (3) 3.85 1.90–7.80 <0.001 1.44 0.45–4.59 0.54
Intracranial hemorrhage 1 (0.0) 100 (1) .x . . .x . .
Intraspinal 0 (0.0) 0 (0) .x . . .x . .
Intraocular 0 (0.0) 0 (0) .x . . .x . .
Retroperitoneal 10 (0.5) 0.0 (0) .x . . .x . .
Hemopericardial or intra-articular 7 (0.3) 28.6 (2) 3.51 0.87–14.18 0.077 2.64 0.62–11.17 0.19
Intramuscular 0 (0.0) 0 (0) .x . . .x . .
6 patients with fatal bleeding (BARC type 5) were excluded from the analysis. *Kaplan-Meier estimates. yIn all multivariable analyses except those concerning the prognostic value of CABG-related bleeding
and its data elements, adjusted HRs were calculated by using Cox regression analyses adjusting for the variables in Online Table 2. zFor bleeding classiﬁcations with a separate category for CABG-related
bleeding (i.e., BARC, TIMI), the prognostic value of the individual data elements of non–CABG-related bleeding was assessed in patients who did not undergo CABG during the index admission. xHRs were not
computable. jjThe prognostic value of CABG-related bleeding and data elements of CABG-related bleeding was assessed separately in patients who underwent CABG during the index admission. Patients who
underwent CABG during the index admission but did not experience a CABG-related bleeding were considered the reference category. {Adjusted HRs were calculated by using Cox regression analyses
adjusting for previous MI, anemia, and the number of days until CABG.
RBC ¼ red blood cell (transfusion); other abbreviations as in Tables 1 to 4.
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1873(8). The fact that BARC-deﬁned bleeding complications
occur more frequently in STEMI patients compared with
unstable angina/non–ST-segment elevation myocardial
infarction patients or patients undergoing elective PCI is
consistent with previous studies showing higher bleeding rates
in STEMI patients according to traditional bleeding deﬁni-
tions (19). Factors contributing to the higher bleeding rate in
STEMI patients include the emergent setting of PCI, greater
prevalence of cardiogenic shock and renal failure, more
aggressive antithrombotic therapy, and use of an intra-aortic
balloon pump for hemodynamic support (20). The lower
BARC bleeding rates in the study by Ndrepepa et al. (8) can
also be explained by the fact that their study population con-
sisted of a clinical trial population, whereas the present study
population consisted of a real-world patient cohort. These
real-world populations generally consist of a sicker population
compared with those of randomized controlled trials (21).
Comparison of the prognostic value of bleeding events
according to the BARC, TIMI, GUSTO, and ISTH
bleeding classiﬁcations. Consistent with the study by
Ndrepepa et al. (8), we found mortality to be increasing with
increasing BARC type. Regardless of the applied bleeding
classiﬁcation, in-hospital bleeding was associated with
mortality according to univariable analysis, but after multi-
variable adjustment, ISTH, GUSTO, TIMI minor, and
BARC types 2, 3a, and 4 bleeding were no longer associated
with 1-year mortality. Thus, most of the excess mortality inpatients with bleeding could be explained by factors asso-
ciated with high mortality in patients with bleeding, such as
cardiogenic shock and acute renal insufﬁciency (22). Both
TIMI major bleeding and BARC type 3b or 3c bleeding
were associated with a 2-fold higher risk of 1-year mortality
according to multivariable analysis. Both these deﬁnitions
include bleeding with a hemoglobin decrease 5 g/dl, which
was the data element with the strongest association with
mortality. Both the BARC 3b and ISTH major bleeding
deﬁnition include hemopericardial bleeding as a data
element, and all bleeding deﬁnitions include intracranial
hemorrhage as a data element. Clearly, intracranial and
hemopericardial bleedings can have a direct fatal outcome
(22,23). These bleeds are rare, however, and it is therefore
possible that we could not demonstrate a signiﬁcant rela-
tionship between these bleeding complications and subse-
quent mortality. BARC type 3b bleeding is also deﬁned by
the use of vasoactive agents to control hypotension.
Although nonsigniﬁcant by conventional statistical stan-
dards, this data element was associated with a 2-fold higher
risk of mortality in the present study. It is conceivable that
this data element identiﬁes bleeds characterized by severe
blood loss, and it is intuitive that this condition is associated
with high mortality (24,25). Interestingly, bleeding resulting
in hemodynamic compromise but not requiring the use of
intravenous vasoactive agents (part of the GUSTO severe
bleeding deﬁnition) was not associated with mortality. This
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1874ﬁnding suggests that bleeding complications which could be
stabilized without the need for inotropes are not associated
with mortality. Data elements that identiﬁed smaller
bleeding complications (e.g., bleeding complications with a
modest declines in hemoglobin [between 2 and 5 g/dl])
were not associated with mortality. This is consistent with
the ExTRACT–TIMI 25 (Enoxaparin and Thrombolysis
Reperfusion for Acute Myocardial Infarction Treatment–
Thrombolysis In Myocardial Infarction 25) study in which a
TIMI minor bleeding (hemoglobin decrease of 3 to 5 g/dl)
was not associated with mortality (22).
Bleeding deﬁnitions in the context of STEMI. BARC
type 3b is deﬁned by blood loss resulting in hemodynamic
compromise requiring the use of vasoactive agents. Up to 5%
to 8% of STEMI patients undergoing PPCI (7.7% in the
present study) develop cardiogenic shock, and these patients
are often treated with intravenous vasoactive agents (26).
When a patient with cardiogenic shock treated with intra-
venous vasoactive agents coincidentally develops a bleeding
complication, it can be challenging to determine whether the
vasoactive agents were administered for cardiogenic shock or
for the bleeding complication, or for both. Thus, in the
setting of PPCI for STEMI, the association between
BARC type 3b bleeding and mortality may be confounded
by the prescription of vasoactive agents for cardiogenic
shock. Likewise, a hemoglobin decrease not related to
bleeding occurs frequently in STEMI patients, especially
in patients with cardiogenic shock and patients admitted to
an intensive care unit (27–29). In the present study, up to
20% of patients had a hemoglobin decrease of at least 3 g/dl,
and almost 40% of these patients had no observed blood
loss. Possible explanations for the hemoglobin decrease
in these patients include hemodilution, frequent blood
sampling, and treatment with nitroglycerin (27–32). In
critically ill STEMI patients admitted to an intensive care
unit who experience a hemoglobin drop caused by the
aforementioned nonbleeding causes and who coincidentally
develop minor bleeding (e.g., an access site hematoma
<5 cm in diameter), one cannot determine whether the
hemoglobin decrease was the result of bleeding or of non-
bleeding causes. Consequently, in the setting of STEMI, the
high mortality after bleeding with a large hemoglobin
decrease (5 g/dl) can be attributed in part to the high
mortality of critically ill STEMI patients with a hemoglobin
decrease not related to bleeding.
Prognostic value of CABG-related bleeding. We found
that as many as 45% of patients undergoing CABG during
the index admission developed a BARC- or TIMI-deﬁned,
CABG-related bleeding event (of which 1 was fatal). Thus,
in patients undergoing CABG in whom dual or triple anti-
platelet therapy often cannot be discontinued in a timely
manner before surgery, the occurrence of CABG-related
bleeding is a frequent complication. Mortality was 4 to 5
times higher in those who experienced a CABG-related bleed
compared with those undergoing CABG without bleeding.
Most of the patients who developed a CABG-relatedbleeding event underwent CABG on the day of presenta-
tion (i.e., they underwent emergency CABG), whereas those
who did not develop a CABG-related bleed underwent
CABG in a more elective setting. After adjustment for timing
of CABG and other confounders, in-hospital CABG-related
bleeding was no longer associated with mortality. Therefore,
it is likely that the high mortality after CABG-related
bleeding is at least in part attributable to the high-risk cir-
cumstances associated with emergency CABG and to the
indication for which patients underwent emergency CABG
(e.g., ongoing ischemia, cardiogenic shock, PCI failure,
mechanical complications) (33).
Study limitations. Data collection occurred retrospec-
tively. Prospective evaluation of the BARC bleeding
classiﬁcation might have yielded systematic serial hemo-
globin measurements. However, we had at least 2 hemo-
globin measurements in >1,900 of 2,002 patients. In
addition, we believe that in patients with observed blood
loss, physicians are more inclined to perform frequent
hemoglobin measurements because this test is clinically
indicated. Therefore, ample hemoglobin measurements
were available in those with bleeding complications.
Source documentation available for adjudication of events
consisted of data recorded as part of routine clinical care.
Prospective data collection might have yielded better
source documentation to better classify BARC bleeding
complications. Nevertheless, even in prospective studies,
many bleeding complications occur in local (referring)
hospitals (or in other settings) where the trial protocol
often is not applied and the source documentation avail-
able to the clinical event committee consists of data
collected in the setting of routine clinical care.
Conclusions
The present analysis demonstrated a signiﬁcant 2-fold
higher risk of 1-year mortality after BARC type 3b or 3c
bleeding or TIMI major bleeding in STEMI patients un-
dergoing PPCI. This high risk, however, did not translate
into a substantial improvement in overall measures of mor-
tality prediction. ISTH- and GUSTO-deﬁned bleeding
complications were not signiﬁcantly associated with mor-
tality. Data elements associated with high mortality were
intracranial or hemopericardial bleeding, bleeding requiring
the use of intravenous vasoactive agents, and bleeding
resulting in a large decrease in hemoglobin levels.
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